Krsnaa Diagonistics Latest Updates

Major Governance & Leadership Restructuring The company undertook an extensive corporate governance overhaul following its recent board meetings. Effective late April 2026, Krsnaa Diagnostics reconstituted all five of its core board committees under new leadership structures. This structural update included the formal appointments of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors to enhance regulatory oversight. Top Management Transitions The management team has seen significant transitions over the last few months. Mr. Chandra Prakash Singh has been integrated into the executive leadership team as the Interim Chief Financial Officer following the resignation of the long-standing CFO, Mr. Pawan Daga. Additionally, the company processed the departure of its Head of Investor Relations, Mr. Vivek Jain, in late March. Executive Chairman Re-appointment The board approved the re-appointment of Mr. Rajendra Mutha as the Executive Chairman of the company for a consecutive five-year tenure, running from April 26, 2026, to April 25, 2031. The leadership extension was executed following the recommendations of the Nomination and Remuneration Committee and was formalized through a completed postal ballot voting process. ₹430 Crore NCD Allotment to ADB Krsnaa Diagnostics officially closed and finalized the allotment of unlisted, secured Non-Convertible Debentures (NCDs) valued at ₹430 crore. The capital infusion, which was executed on a private placement basis, was formally completed via the company's Operations Committee following strategic investment approvals from the Asian Development Bank (ADB).